Antileukinate 

Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury^[1][2][3].

Antileukinate inhibits the binding of human eotaxin to human eosinophils with an IC₅₀ of 8.2 μM^[2].
Antileukinate (10-100 μM; 2 hours) significantly suppresses eosinophil chemotaxis to human eotaxin^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Antileukinate (52.63 mg/kg; s.c.) protectes mice against acute pancreatitis and associated lung injury^[1].
Antileukinate (5mg/kg; s.c.) inhibits the interaction between murine eotaxin and murine eosinophil^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1003.19

C₄₅H₆₆N₁₈O₇S

138559-60-1

Ac-RRWWCR-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Madhav Bhatia, et al. Treatment with antileukinate, a CXCR2 chemokine receptor antagonist, protects mice against acute pancreatitis and associated lung injury. Regul Pept. 2007 Jan 10;138(1):40-8.  [Content Brief]

  [2]. Yuji Fukuno, et al. Chemokine receptor inhibitor, Antileukinate, suppressed ovalbumin-induced eosinophilic inflammation in the airway. Cytokine. 2003 Jun 7;22(5):116-25.  [Content Brief]

  [3]. S HayashiY, et al. Antileukinate, a hexapeptide inhibitor of CXC-chemokine receptor, suppresses bleomycin-induced acute lung injury in mice. Lung. 2002;180(6):339-48.  [Content Brief]